Relative effectiveness of additive pain interventions during vaccination in infants
- PMID: 27956393
- PMCID: PMC5305402
- DOI: 10.1503/cmaj.160542
Relative effectiveness of additive pain interventions during vaccination in infants
Abstract
Background: Vaccine injections can cause acute pain and distress in infants, which can contribute to dissatisfaction with the vaccination experience and vaccine hesitancy. We sought to compare the effectiveness of additive pain interventions administered consistently during vaccine injections in the first year of life.
Methods: We conducted a multicentre, longitudinal, double-blind, add-on, randomized controlled trial. Healthy infants were randomly assigned to 1 of 4 levels of pain management for all vaccine injections at 2, 4, 6 and 12 months: (i) placebo control; (ii) parent-directed video education about infant soothing; (iii) the video plus sucrose administered orally or (iv) the video plus sucrose plus liposomal lidocaine applied topically. All infants benefit from injection techniques that minimize pain. We used a double-dummy design; hence all parents watched a video (active psychological intervention or placebo) and all infants received oral solution (sucrose or placebo) and topical cream (lidocaine or placebo). We assessed infant distress during 3 phases - preinjection (baseline), vaccine injection (needle), and 1 minute postinjection (recovery) - using the Modified Behavioural Pain Scale (range 0-10). We compared scores between groups and across infant ages using a mixed-model repeated-measures analysis.
Results: A total of 352 infants participated in the study, from Jan. 17, 2012, to Feb. 2, 2016. Demographics did not differ among intervention groups (p > 0.05). Baseline pain scores did not differ among intervention groups (p = 0.4), but did differ across ages (p < 0.001). Needle pain scores differed among groups (p = 0.003) and across ages (p < 0.001). The mean (± standard deviation) needle score was 6.3 (± 0.8) in the video-sucrose-lidocaine group compared with 6.7 (± 0.8) in each of the other groups. There were no other between-group differences. Recovery scores did not differ among groups (p = 0.98), but did differ across ages (p < 0.001).
Interpretation: Only liposomal lidocaine provided consistent analgesia within an additive pain intervention regimen during vaccinations in infants. Trial registration: ClinicalTrials.gov, no. NCT01503060.
© 2017 Canadian Medical Association or its licensors.
Conflict of interest statement
Anna Taddio declares a research grant from Pfizer, and study supplies from Natus and Ferndale. The other authors declare no conflicts of interest.
Figures

Comment in
-
Topical Lidocaine Reduces Vaccination Pain in Infants.Am J Nurs. 2017 Apr;117(4):66-67. doi: 10.1097/01.NAJ.0000515239.59418.bb. Am J Nurs. 2017. PMID: 28333750 No abstract available.
References
-
- Jacobson RM, Swan A, Adegbenro A, et al. Vaccine Research Group. Making vaccines more acceptable — methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine 2001;19: 2418–27. - PubMed
-
- Pillai Riddell R, Flora DB, Stevens SA, et al. Variability in infant acute pain responding meaningfully obscured by averaging pain responses. Pain 2013; 154:714–21. - PubMed
-
- Taddio A, Chambers CT, Halperin SA, et al. Inadequate pain management during childhood immunization: the nerve of it. Clin Ther 2009;31(Suppl 2):S152–67. - PubMed
-
- Reducing pain at the time of vaccination: WHO position paper — September 2015. Wkly Epidemiol Rec 2015;90:505–10. - PubMed
-
- MacDonald NESAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine 2015;33:4161–4. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical